People with neuroendocrine tumors have significantly weaker bones than healthy people, with 71% showing poor bone quality and 68% having low vitamin D levels, according to a 2026 cross-sectional study of 41 patients. Gram Research analysis found that patients with higher vitamin D and healthier body weight survived longer without cancer progression, suggesting nutritional status may influence outcomes in these rare tumors.
A new study found that people with neuroendocrine tumors (rare cancers that start in hormone-producing cells) often have weaker bones and less muscle than healthy people. Researchers studied 41 patients with these tumors and compared them to 47 healthy people of similar age and weight. They discovered that 71% of tumor patients had poor bone quality, and many were low in vitamin D. Interestingly, patients with higher vitamin D levels and healthier body weight lived longer without their cancer getting worse. The findings suggest that paying attention to bone and muscle health might help improve outcomes for people fighting these rare cancers.
Key Statistics
A 2026 cross-sectional study of 41 neuroendocrine tumor patients found that 71% had poor bone quality and 59% had early bone loss at the hip, compared to healthy controls matched for age and weight.
According to research reviewed by Gram, 68% of neuroendocrine tumor patients had low vitamin D levels, and those with higher vitamin D levels lived significantly longer without cancer progression.
A study of 41 neuroendocrine tumor patients found that 37% had low muscle mass and patients with advanced-stage disease had significantly weaker bones than those with earlier-stage tumors.
In a 2026 analysis of 41 neuroendocrine tumor patients, higher vitamin D levels and healthier body weight were independently associated with longer progression-free survival, while higher tumor aggressiveness markers predicted shorter survival.
The Quick Take
- What they studied: Whether people with neuroendocrine tumors (rare cancers) have weaker bones and muscles than healthy people, and whether bone health affects how long patients survive without their cancer getting worse.
- Who participated: 41 patients with rare neuroendocrine tumors (average age 72, about half were women) compared to 47 healthy people matched by age, sex, and weight.
- Key finding: According to Gram Research analysis, 71% of tumor patients had poor bone quality, and 68% had low vitamin D levels. Patients with higher vitamin D and healthier weight lived significantly longer without cancer progression.
- What it means for you: If you or a loved one has a neuroendocrine tumor, doctors should check bone health and vitamin D levels as part of regular care. Maintaining healthy vitamin D and body weight may help improve survival outcomes, though more research is needed to confirm this.
The Research Details
This was a cross-sectional study, which means researchers looked at a group of people at one point in time rather than following them over years. The team recruited 41 patients with neuroendocrine tumors (rare cancers that grow slowly in hormone-producing cells throughout the body) and compared 38 of them to 47 healthy people who matched them in age, sex, and body weight.
To measure bone health, researchers used a special X-ray machine called a DXA scanner that takes pictures of bones and measures their density and quality. They also measured vitamin D levels in the blood and calculated muscle mass using a formula based on body measurements. This allowed them to see exactly how bone and muscle health differed between the two groups.
The researchers looked at whether bone problems were connected to how aggressive the tumors were (measured by a marker called Ki-67) and how far the cancer had spread. They also tracked how long patients survived without their cancer getting worse.
This research approach is important because neuroendocrine tumors are rare, and doctors don’t yet know much about how these cancers affect bones and muscles. By comparing tumor patients directly to healthy people, the researchers could identify specific problems that need attention. Understanding these connections helps doctors develop better care plans that address not just the cancer, but also the body’s overall health.
This study has some important limitations to understand. It’s relatively small (41 patients), which means the findings are preliminary and need confirmation in larger studies. Because it’s cross-sectional, researchers couldn’t prove that poor bone health causes worse cancer outcomes—only that they happen together. The study was exploratory, meaning it was designed to identify patterns worth studying more carefully, not to provide definitive answers. The researchers were honest about these limitations and called for larger, longer-term studies to validate their findings.
What the Results Show
The study revealed a striking pattern: 71% of patients with neuroendocrine tumors had poor bone quality (measured by something called trabecular bone score), even when standard bone density measurements looked normal. This means the internal structure of their bones was weaker than it appeared on the surface. Additionally, 59% of patients had osteopenia (early bone loss) at the hip, and 68% had low vitamin D levels—a nutrient essential for bone health.
Patients with more advanced cancer had significantly weaker bones than those with earlier-stage disease. Similarly, patients with grade 2 tumors (medium aggressiveness) had worse bone health than those with grade 1 tumors (slowest growing). Interestingly, 37% of patients also had low muscle mass, suggesting that these tumors affect the entire musculoskeletal system.
When researchers looked at survival, they found that patients with higher vitamin D levels and healthier body weight lived longer without their cancer progressing. In contrast, patients with higher Ki-67 (a marker of tumor aggressiveness) had shorter survival times. The connection between bone quality and tumor aggressiveness was clear: patients with more aggressive tumors had weaker bones.
The study found that age played a role—older patients tended to have weaker bones, which is expected. However, healthier body weight was associated with better bone health and more muscle mass. Low muscle mass was common in the tumor group but wasn’t directly linked to how aggressive the tumors were, suggesting it’s a separate problem that still needs attention.
This is one of the first studies to systematically examine bone health in neuroendocrine tumor patients. Previous research focused mainly on bone metastases (cancer spreading to bones), but this study shows that bone problems occur even without metastases. The findings align with what researchers know about other cancers—that overall nutritional and metabolic health affects survival—but provide new evidence specific to these rare tumors.
The study is small with only 41 patients, making it hard to apply findings broadly. It’s cross-sectional, so researchers couldn’t prove that improving bone health would actually improve survival—only that they’re connected. The study didn’t track patients over time, so we don’t know if bone health changes as the disease progresses. The researchers couldn’t account for all factors that might affect bones, like medications or physical activity levels. Finally, these are exploratory findings that need confirmation in larger, longer-term studies before doctors change their practice.
The Bottom Line
For patients with neuroendocrine tumors: Ask your doctor to check your vitamin D levels and bone health as part of regular care (moderate confidence—based on this exploratory study). Work to maintain a healthy body weight and adequate vitamin D intake through diet or supplements if recommended by your doctor (moderate confidence). For doctors: Consider adding bone health screening to routine care for neuroendocrine tumor patients, especially those with advanced disease (low to moderate confidence—requires larger studies).
This research is most relevant to people diagnosed with neuroendocrine tumors and their doctors. It’s also important for oncologists who treat these rare cancers. People with other types of cancer might benefit from similar bone health screening, though this study doesn’t directly address that. Healthy people don’t need to worry about these findings.
Vitamin D levels can improve within weeks to months of supplementation. Bone density changes typically take 6-12 months to measure. Survival benefits from improved nutrition and vitamin D would likely take months to years to observe. Patients should expect ongoing monitoring rather than quick fixes.
Frequently Asked Questions
Do people with neuroendocrine tumors have weaker bones?
Yes. A 2026 study of 41 neuroendocrine tumor patients found 71% had poor bone quality and 59% had early bone loss, even when standard bone density tests appeared normal. This suggests these tumors significantly impact skeletal health.
Can vitamin D help people with neuroendocrine tumors live longer?
Research shows patients with higher vitamin D levels survived longer without cancer progression, but this doesn’t prove vitamin D causes the improvement. Larger studies are needed to confirm whether vitamin D supplementation directly improves survival outcomes.
What percentage of neuroendocrine tumor patients have low vitamin D?
According to a 2026 study of 41 patients, 68% had low vitamin D levels. This is much higher than in the general population, suggesting neuroendocrine tumors may interfere with vitamin D metabolism or absorption.
Should I get bone density testing if I have a neuroendocrine tumor?
The research suggests yes. Doctors should consider bone health screening for neuroendocrine tumor patients, especially those with advanced disease, as part of comprehensive care. Talk to your oncologist about whether testing is appropriate for you.
Does muscle loss affect survival in neuroendocrine tumors?
Low muscle mass was common in the study (37% of patients), but wasn’t directly linked to tumor aggressiveness or survival. However, maintaining muscle mass remains important for overall health and quality of life during cancer treatment.
Want to Apply This Research?
- Log vitamin D intake (through food and supplements) and vitamin D blood test results quarterly. Track body weight weekly and note any changes. Record bone density test results annually.
- Set a daily reminder to take vitamin D supplements if recommended by your doctor. Log meals high in vitamin D (fatty fish, fortified milk, egg yolks). Schedule quarterly vitamin D blood tests and annual bone density scans.
- Create a health dashboard showing vitamin D levels over time, body weight trends, and bone density scores. Set alerts for vitamin D test appointments and bone scans. Compare results to previous measurements to track progress.
This article summarizes research findings and should not be considered medical advice. Neuroendocrine tumors are rare and complex conditions requiring specialized care. If you have been diagnosed with a neuroendocrine tumor or are concerned about bone health, consult with your oncologist or endocrinologist before making any changes to your treatment plan, supplements, or lifestyle. The findings presented are preliminary and come from a small study; larger research is needed to confirm these results and establish clinical recommendations. Always discuss vitamin D supplementation, dietary changes, and bone health screening with your healthcare provider, as individual needs vary based on your specific diagnosis, stage of disease, and other medical factors.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.